α-catenin 557
α-fetoprotein 1086
α-MSH 2004
α-tocopheryl succinate 1822
1100delC 1966
19F magnetic resonance spectroscopy 754
19F MRS 1796
5-aminolaevulinic acid 405, 730
5-fluorouracil 239, 455, 754, 803, 944, 992, 1796, 2213
5-FU 816
72 kDa type IV collagenase 1270
7271T>G mutation 1513
A3 adenosine receptor 1552
abdomino-perineal resection 2019
ablation 2227
abnormal nucleation 1802
accelerated proliferation 2184
acceptability 1400
ACIS 886
actin 860
acute hypoxia 350
adenocarcinoma 834, 2078
adenoviral cytolysis 577
adenovirus 385, 1162, 2140
adjuvant 1837
adjuvant chemotherapy 2062
adjuvant therapy 1042, 1433
adrenomedullin 1927
adriamycin 1423
adult height 81
adult leg length 81
adult trunk length 81
advanced cancer 23
advanced disease 77
advanced gastric cancer 2207
advanced gastrointestinal cancer 2051
advanced melanoma 1901
advanced NSCLC 2190
Africa 65
aggregation state 937
AIDS 94, 505
AKT 185, 391, 2110
ALA efflux 173
ALA uptake 173
albumin 1028
alcohol 1667
allelic loss 2289
alpha-interferon 50
alveolar soft-part sarcoma 243
anal carcinoma 2057
anatomic site 1202
androgen deprivation 971
androgen-independent cell 1566
androgen receptor 552
aneusomy 128
angiogenesis 215, 1375, 1395, 1927
angiopoietins 891
annexin V 1327
anthracyclines 36, 666
anthropometry 519
antiangiogenesis 1395
antiangiogenic 262, 907
antiangiogenic activity 243
antibody–cytokine fusion protein 1130
antibody response 291
antigens 199
antioxidants 1255
antiproliferative 907
antisense oligonucleotides 1352
antitumour effect 1102
AP-2 transcription factor 899
APC 1298
Apo2L/TRAIL 206
apoptosis 178, 192, 206, 363, 564, 727, 763, 915, 944, 1035, 1091, 1108, 1327, 1345, 1358, 1366, 1590, 1620, 1757, 1776, 1802, 1817, 1822, 1896, 1950, 1979, 2155, 2244, 2277
apoptosis resistance 1714
apoptosome 2147
arginine 907
arginine deiminase 907
arginine deprivation 573
arthropometry 81
aspirin 1705
association 1524
astrocytoma grade II 128
ataxia telangiectasia 1091
ATM gene screening 1513
ATP-TCA 2299
autologous transplantation 29
axilla 1310
β-catenin 152, 557, 1298
β1-integrin 374, 2122
β3-integrin 2122
B cell lymphoma 2155
B16-F10.9 melanoma 314
bacteriochlorophyll 2333
Barrett's oesophagus 1508
Bax 1590
BCG immunotherapy 2312
BCL-2 55, 391
Bcl-xL 1352
BCRP/MXR/ABCP/ABCG2 1971
Belarus and Ukrainian registries 2098
benign prostatic hypertrophy 106
best supportive care 2219
betel chewing 1202
betel quid 681
bilateral breast cancer 1513
biomarkers 8, 1940
biopsy 8
birth weight 1664
bispecific antibody 1987
bisphosphonates 178
biweekly schedule 239
bladder cancer 298, 1096, 1290, 2264, 2271, 2312
blindness 2038
blood flow 2333
blood pressure 1243
body mass index 513, 519, 1667
body size 852
bone markers 2031
bone marrow 539
bone metastases 178, 625, 660
BRAF 1958
brain 1743
brain tumour 577
breast 277, 524
breast cancer 15, 77, 81, 135, 178, 185, 192, 284, 305, 492, 508, 533, 539, 648, 666, 840, 847, 977, 983, 1035, 1185, 1255, 1513, 1627, 1645, 1664, 1686, 1693, 1750, 1789, 1920, 1934, 2062, 2289
breast cancer genetic risk counselling 653, 1650
breast cancer in young women 1661
breast cancer risk 1672
breast carcinomas 113, 660, 1502, 2227
breast density 852
breast neoplasms 271, 487
breast tumour 1310
bronchoscopy 1885
brostallicin 1559
brush border 1995
bryostatin-1 1152, 1418
C26 murine colon carcinoma 754
Ca19-9 1413
CA9 877
cachexia 1116
calcitriol 968
caloric restriction 1375
calorie restriction 2254
camptothecin 1757
cancer 120, 1147, 2045
cancer awareness 2165
cancer cachexia 2254
cancer care 821
cancer diagnostics 1067
cancer incidence 1709
cancer of oral cavity and oropharynx 1667
cancer pain 2027
cancer patients 1055
cancer relative survival 74
cancer risk 308
cancer vaccine 1079
canine 1530
capecitabine 615, 1627, 1843
carbonic anhydrase IX 2, 1067, 1290
carboplatin 803, 1901
carcinoid 455
carcinoid tumours 1383
carcinoma 524, 1610
case–control 88, 1255
case–control studies 23, 831, 840, 2087, 1228
caseload 15, 492
caspase-9 1366
caspases 2147
cathepsin 1574
Caveolin 1909
CB1954 944
CD151 158
CD1a 533
CD26/DPPIV 1366
CD4 1736
CD40 ligation 1162
CD8 1736
CD95 363, 1950
CDDP 2207
cDNA array 564
cell cycle 120, 564, 763, 1091, 1920, 2305
cell death 1574, 1590
cell lines 2289
cell surface molecules 1463
cell-cycle 1776
cell-death assay 1789
c-erbB-2 513, 959
cervical cancer 101, 834, 1248
cervical cancer screening model 1830
cervical cytology 88
cervical intraepithelial neoplasia 109
cervix 65
cervix neoplasms 2078
CF101 1552
checkpoint 1966
CHEK2 1966
chemically induced hepatocellular carcinoma 730
chemically induced squamous cell carcinoma 2320
chemoprevention 412, 1705
chemoradiation 1433
chemosensitivity test 1896
chemotherapy 206, 477, 634, 727, 840, 966, 968, 1035, 1192, 1428, 1439, 1517, 1605, 1627, 1849, 2038, 2045, 2057, 2299
child 2038
childhood cancer 1215, 1228
Chinese 1686
Chlamydia trachomatis 831
choroid plexus 1743
choroid plexus tumour 1743
chromosome 17 720, 1530
chronotherapy 1870
cigarette smoking 1202
CIN 831
cinical benefit 2207
cisplatin 585, 617, 795, 1192, 1633, 1860, 2045
cisplatinum 1849
citrulline 573, 907
classic Kaposi's sarcoma 1657
clear cell sarcoma 1072
clinical nurse specialist 15
clinical trial 8, 1152
clonotypic PCR 1876
clorgyline 1979
cluster analysis 305
CMF 1837
CML 1162, 1855
c-Myc 1479
Coexisting CIN 886
cognition 971
cohort analysis 1260
cohort study 465, 505, 1221, 1238, 1664, 1709
colitic cancer 1232
collaboration 15
collagen crosslinks 1722
Colo 205 1995
colon 1358
colon cancer 158, 374, 1352, 1439, 2277
colon carcinoma 363, 1552
colorectal adenoma 152
colorectal cancer 23, 465, 477, 612, 707, 1232, 1638, 1870, 1876, 2299
colorectal cancer patients 1400
colorectal carcinoma 146, 992, 1155, 2051
colposcopy 109
combination chemotherapy 795, 992
combination regimens 1789
combretastatin A-4 1334
comet assay 2264, 2271
communication 2069
communication skills training 1445
comparative genomic hybridisation (CGH) 720, 864, 1530
compliance 497
computed tomography scan 482
computer-aided detection 1645
concomitant drugs 1013
concurrent chemoradiation 795
conflict of interest 1405
confocal fluorescence microscopy 1581
consensus method 821
continuous infusional 5-flourouracil 2051
contralateral breast cancer 513
controlled-release morphine 2027
controlled-release oxycodone 2027
core biopsy 1310
cost – benefit analysis 109
cost-effectiveness 634
cost-minimisation 1002
COX-2 1358
CpG island methylation 338
CpG-oligonucleotides 2312
CPT-11 2178
C-reactive protein 612, 1028
CT antigen 291
CTL 1079
culture 539
cumulative prognostic score 1028
cyclin D 1995
cyclin D1 1920
cyclooxygenase-2 1102
CYP1B1 1524
CYP3A4 1855
cytochrome P450 1855
cytokeratin 539
cytokines 524, 1463
cytological grading 36
cytology 109
cytosine deaminase 1796
cytoskeleton 860
cytostatic 1995
cytotoxic 1166
cytotoxic drugs 2133
cytotoxicity 199
δ-aminolevulinic acid 173
D122 Lewis lung carcinoma 314
DAXX 1950
DCE-MRI 1889
DCIS 277, 1920
DcR2 206
death receptors 1714
DEB theory 2254
decision-making 2219
deficiency 573
degradative enzymes 1123
deletion 1729
dendritic cells (DCs) 533, 1162, 1172, 1463, 1736
depletion 1633
deprivation 612, 1650
desmoplastic small round-cell tumour 1159
dextran derivative 215
diagnosis 1645, 1885
diagnostic 2098
diagnostic classification 1599
diet 1255, 1672
differentiation 140, 146
dihydropyrimidine dehydrogenase 816, 1486
dissociation 1817
D-loop 697
DNA damage 333, 1366, 1479, 2271
DNA microarrays 314
DNA minor groove binder 1559
DNA mismatch repair 1559
DNA repair 333
DNA strand breaks 2277
docetaxel 630, 795, 968
dog 1530
domiciliary 2190
dominant negative 1276
dose individualisation 787
dose intensity 2062
dosimetry 840
doxifluridine 1627
doxorubicin 357, 1545, 2140
drug distribution 1581
drug resistance 185, 1581
drug sensitivity 1559
drug-resistance 1971
DSB 593
Du145 593
dysplasia 1232
E2F 120
early breast cancer 1837
early diagnosis 1048
early life risk 81
EBV gene expression 113
E-cadherin 557
ECF 1433
ECOG 1022
economic evaluation 634
effectiveness 88
EGFR 681, 1285, 2327
EGTR 1776
elderly 1428, 1439, 1827
elderly patients 992
ELISPOT assay 1172
endogenous granzyme B 135
endometrial cancer 891, 2023
endometrial carcinoma 697
endometrial hyperplasia 891
endometrial neoplasms 1697
endothelial growth factors 426
energy expenditure 2254
EORTC QLQ-C30 497
EPA 1116
ependyma 1743
ependymoma 1743
epidemiology 94, 101, 1205, 1221, 1243, 1661, 1705
epidermal growth factor receptor 1266
epidermal/mucosal reactions 1102
epidermoid carcinoma A431 cells 215
epirubicin 617, 1192
epithelium 707
Epstein–Barr virus (EBV) 344, 1200
ERBB2 promoter 899
ET-743 2305
ethnic origin 641
ethnicity 70, 508
EWS/ATF1 1072
ex vivo 1789
excimer dye laser 730
expression 1729
extracapsular dissection 1610
extragonadal germ cell tumours 29
facial nerve palsy 1610
FADD 1950
faecal occult blood 23
familial prostate cancer 691
fas ligand 1345
fat 1672, 1686
FcγRI 2234
febrile neutropenia 43
fermented wheat germ extract 465
FGFR3IIIc 1276
FGFR3IIIS 1276
Fhit 320
fibroblasts 1473
fish 1686
flavones 1255
flavonoids 1255
flow cytometry 1971
fluoropyrimidine 615, 1843
fluoropyrimidine-based chemotherapy 1486
fluorouracil 585, 615, 1155
focal adhesion kinase 140
focused ultrasound surgery 2227
FOLFOX4 455
folinic acid 239
follicular lymphoma 36
follow-up 482
Foscan 398
FOXO1A 327
fruits 1209
functional classes 1940
fund raising 2165
γ-irradiation 727
G2/M checkpoint 1479
gadopentetate dimeglumine 1889
gallbladder cancer 1736
gastric cancer 676, 1314, 1428, 1433, 2051
gastritis 1314
gastrointestinal neoplasms 426
gastrointestinal stromal tumours 460
G-CSF 2234
gef gene 192
gefitinib 1827
gelatinase A 1270
gemcitabine 239, 1180, 1192, 1413, 1865, 2190, 2299
gene amplification 552
gene expression 314, 564, 1508, 1914
gene expression profiling 1599
gene therapy 192, 2155
genetic testing 1400
Germany 1205
germ-cell tumours 787, 1849, 2202
gestational trophoblastic disease 2197
Gleason score 106
Gleevec 1855
glioblastoma 1896, 2122
glioma 248, 727, 922, 1172, 1375, 1896
Glivec 634, 1403, 1855
glucose transporter protein 1 (GLUT1) 1290
GLUT-1 870
glutathione 1108
GM-CSF 1162
grade 1096
graded-field gel electrophoresis 593
growth 852
growth factor 178
growth hormone 524, 1108
growth pattern 1920
GSK3β 1298
GSTM1 1502
GSTT1 1502
HAART 457
haematological 1389
haemoglobin 977
haemolymphopoietic neoplasms 94
haemolysis 1334
haplotype 1524
HCT-15 1995
head and neck cancer 585
head and neck squamous cell carcinoma 864
health economics 1405
heat shock cognate protein 70 1079
HeLa 593
Helicobacter pylori 1314
hepatectomy 1493
hepatic artery chemoembolisation 1423
hepatic neoplasms 1423, 1493
hepatocellufalar carcinoma 1614
hepatocellular carcinoma 291, 730, 1086, 1865
hepatocyte culture 1493
hepatocyte injury 1423
Her-2 681
hereditary 1524
hereditary nonpolyposis colorectal cancer 1400
HER-2/neu 666, 983, 2110
HER-2/neu 959, 2234
HER-2/neu peptides 1055
HER2/neu 1305
HIF 877
high-dose carboplatin 787
high-dose chemotherapy 29, 787, 1159
high-grade cervical dysplasia 1062
high grade intraepithelial lesions 101
high-intensity focused ultrasound 2227
histology 109
HIV 457, 502, 505
HLA-A26 1055
HLA-A3 1055
HLA-B46 1079
HMGA2 2104
hnRNP K protein 1493
Hodgkin's disease 482
hormone replacement therapy 1697
hormone-resistant prostate cancer 552
hormones 1147
hPif1 713
HPV 831, 1248
HPV genotypes 886
HRT 277
HSP27 1950
HSV-TK 1086
HT-29 1995
hTERT 922, 1473
human 899
human catalase 2140
human glioma cell line 1802
human mammary epithelial cells 1479
human monoclonal antibody 1545
Human papillomavirus 101
human papillomavirus 1830
human papilloma virus load 109
human papillomavirus-16 672
Hurthle cell carcinoma 258
HUVECs 357
hyperbilirubinaemia 1403
hypermethylation 1473
Hypersensitivity reaction 477
hyperthermia 405, 2333
hypomagnesaemia 1633
hypopharynx 1940
hypoxia 271, 870, 1290, 2133
hypoxia-inducible factor 2
hypoxia-inducible-factor 1α 1042
I157T 1966
IAP 2147
ICBP90 120
IGF-1 1375
IL-12 1552
IL-2 1876
IL-6 338
imatinib 460, 1403, 1855
immortalization 2293
immune privilege 1345
immunochemical test 23
immunocytochemistry 899
immunocytokine 1130
immunohistochemistry 140, 320, 546, 1042, 1729, 1736, 1927, 2249
immunoliposomes 1545
immunostaining 2104
immunotherapy 385, 1130, 1147, 1162, 1172, 2213, 2234
imprint cytology of biopsied sample 1885
incidence 70, 834, 1205
induction chemotherapy 2184
infants 1605
infertility 1849
infrared-A-radiation 405
In situ hybridisation 128, 891
insulin 1697
insulin-like growth factor binding protein-1 (IGFBP-1) 1697
insulin-like growth factor binding protein-3 (IGFBP-3) 1697
insulin-like growth factor-I (IGF-I) 1697
interferon alpha 2213
interferon alpha-2b 243
interleukin-2 50, 1620, 2213
interstitial fluid pressure 1334
intestinal metaplasia 1314
intralesional therapy 1620
intramuscular administration 1228
invasion 1123, 1270, 2122
invasive lymphocytes 113
in vitro 2133
ionising radiation 1102, 1479, 1802
ionizing radiation 1709
‘Iressa’ 585
Irinotecan 617, 630, 992, 997, 1008, 1439, 1860, 1870
Israeli Jews 1657
IVS10-6T>G mutation 1513
JAK/STAT pathway 338
Japanese population 691
jaundice 1403
JCOG 2178
JNK 1950
KAI1/CD82 158
Kaplan-Meier 232
Kaposi's sarcoma 502
keratinocytes 1473
ketogenic diet 1375
Ki-67 index 128
kidney cancer 1418
kidney tumour 1285
KIT gene 460
knockout mice 1776
KSHV 1657
KSHV/HHV-8 502
lactate dehydrogenase 877
language of consultation 641
laryngeal brushing 1048
larynx 1048
laser scanning cytometry 8
l-deprenyl 1979
leadership 15
leanness 1667
leukaemia 1228, 1638
lichen sclerosus 2249
life-course 852
LIG-1 1285
linkage 505
lipiodol 1423, 1614
liposarcoma 1409
liposomal doxorubicin 1180
liver metastases 284
LKB1/STK11 308
LNCaP 593
local tumour control 2019
loss of heterozygosity 333, 2289
low-dose methotrexate 2197
low-risk 43
lung cancers 320, 702, 795, 959, 1013, 1022, 1705
LVT 930
lymphangiogenesis 426
lymphatic system 426
lymph node metastasis 1042, 1750, 2116
lymphoma 1530, 2087
lysosomes 1574
magnesium 1633
malignancies 1389
malignant effusion 1876
malignant fibrous histiocytoma 720
malignant transformation 2293
mammary cancer 385
mammographic parenchymal patterns 852
mammography 1645
MAPK 185
marine natural compounds 763
matrix metalloproteinase-2 2122
matrix metalloproteinase-7 2116
matrix metalloproteinase-9 2116
MBD2 1934
MCF-7 593
MC1R 1961
MDX-H210 2234
MeCP2 1934
mediastinal primary 29
megakaryocytic differentiation 1320
mEH 702
melanocortin 2004
melanocytes 1072
melanoma 573, 1123, 1517, 2004
melanoma-follow-up 1457
melanoma-prognosis 1457
men 1243
MET 327
meta-analysis 55, 101, 1672
meta-iodobenzylguanidine 1383
metabolic control 1375
metabolic status 2333
metabolism 573
metastasis 314, 557, 1270, 1909, 2004
metastatic bone disease 2031
metastatic colorectal cancer 1486
metastatic gastric cancer 997
methyl-CpG-binding protein 1934
MIBG 1383
microarray 1599, 1757, 1914
microenvironment 2
micrometastasis 676
micronuclei 727
microsatellite instability 707
midkine 1086
migrants 508
migration 1123
minichromosome maintenance protein-2 1048
missing data 781
MITF 1072
mitochondrial DNA 697
mitochondrial microsatellite instability 697
mitogen-activated protein kinase (MAPK) 1783
mitomycin C 2051, 2299
mitoxantrone 1971
MMP 1817
MMP-2 1123
molecular epidemiology 702
molecular mechanisms 585
monoamine oxidase inhibitors (MAOIs) 1979
MonoHER 357, 2140
morbidity 648
morphology 1693
mortality 77
mouse 1796
mouth 2244
MRP-1/CD9 158
MTC 2093
m-THPC 398
MTT 357, 2140
MUC1 1130
multidisciplinary team 15
multivariate analysis 1166
mutations 308, 1729, 1958, 1971, 2249
myeloprotection 1552
myogenesis 327
n-3 fatty acids 1686
n-3 polyunsaturated fatty acids 1102
n-6 fatty acids 1686
N-telopeptide 2031
Na+/H+ antiporter 1395
nasopharyngeal carcinoma (NPC) 344
natural killer cells 1130, 1552
natural killer cells (NKCs) 1736
natural regression 1062
NE tumours 1776
neoadjuvant chemotherapy 1185
neonatal cardiac myocytes 2140
neoplasms 1243, 1260
neoplastic disease 1822
neuroblastoma 412, 470, 860, 1605
neuroendocrine tumour 455
neuropsychology 2038
neutropenia 1837, 2062
neutrophil adhesion 357
neutrophils 1345
NF-kappaB 2004
NF-κB 391, 1108, 1116, 1358
NICE 966
nitroreductase 944
NO 907
node-positive breast cancer 268
noncytotoxic 1166
non-Hodgkin 2087
non-Hodgkin lymphoma 713
non-Hodgkin's lymphoma 1958
nonimmune cells 135
nonseminomatous histology 29
non-small-cell lung cancer 55, 246, 457, 877, 1008, 1028, 1192, 1789
normal cells 1147
normal ovary 1298
normoxia 2133
Norway 1238
Nottingham prognostic index 1185
NSAIDs 1358
NSCLC 1827, 2184
Ntx 2031
nucleophosmin/B23 1320
nude mice 1383
obesity 519
occupational exposures 1215
octreotide 258
oesophageal adenocacenoma 1508
oesophageal adenocarcinoma 1729
oesophageal cancer 140, 630, 1202, 1209, 2299
oesophageal squamous cell carcinoma 1042
oesophagus 2045
oestrogen and progesterone receptor status 1661
oestrogen receptor 113, 1934
OK-432 1876
oligodendroglioma 2327
O6-methylguanine-DNA-methyltransferase 1517
oncogenes 1305, 1958
oncogenesis 1395
oncologist 1022
oncology 1405
optic pathway glioma 2038
oral 808, 1627
oral antibiotics 43
oral cancer 681
oral mucosa 2244
oral squamous cell carcinoma 557, 1722
organ transplantation 1221
orotate phosphoribosyl transferase 1486
osteosarcoma 206
OT 930
outcome and process assessment (health care) 15
outpatient 43
ovarian cancer 966, 1002, 1152, 1180, 1298, 1843, 2293
ovarian malignancy 672
ovarian neoplasm 1002
ovarian surface epithelium 2293
overexpression 1574
oxaliplatin 1155, 1439, 1870
oxygenation 2333
oxygen consumption 937
oxygen tension 350
oxytocin receptor 930
p16 1802
p185 959
p21 WAF1/CIP1induction 1566
p21 WAF1/CIPI-deficit cell 1566
p21 Waf1/Cip1 1757
p31 EBV DNA 113
p38MAPK 564
p53 320, 707, 727, 1314, 1729, 2249
p53 tumour suppressor gene 672
paediatric Hodgkin's lymphoma 1200
palladium-bacteriopheophorbide 2320
palliative care 2069
palliative chemotherapy 1860, 2219
pancreas cancer 391, 1987
Pancreatic adenocarcinoma 239, 1714
pancreatic cancer 1413, 1860, 2104, 2110
pancreatic ductal adenocarcinoma 338
pancreatic neoplasms 519
papillomavirus 94
Pap smears 88
parotid gland 1610
patient-doctor communication 2202
patient participation 2069
patient preferences 1450
patient selection 1860
PAX3 327
PAX7 327
PCR 1750
pegylated liposomal doxorubicin hydrochloride 1002
performance status 1022, 1028
period analysis 1260
period survival 74
peripheral benzodiazepine receptor 564
peripheral lung cancer 1885
peritoneal cytology 2023
PET 8
PET imaging 1327
Peutz–Jeghers syndrome 308
P-glycoprotein 1581
pH 2
pharmaceutical targets 1940
pharmacodynamics, hamster tumour model 2320
pharmacokinetics 398, 816, 1776, 1822, 1855
phase I study 617, 1901
phase I/II study 2051
phase II 997, 1428
phase II study 1008
phase II trial 1418
phase III trial 1192
phase one 1166
phenylacetate 412
phenytoin 615
pheochromocytoma 1383
phosphatidylserine 1327
phospholipase A2 (PLA2) 1783
phospholipase C (PLC) 1783
photodynamic diagnosis 730
photodynamic therapy 173, 398, 405, 937, 1590, 2320, 2333
photodynamic therapy (PDT) 730
photosensitiser 937, 2320
pH regulation 1395
phthalocyanine Pc 4 1590
physical activity 847
physician patient relations 2069
pimonidazole 1290
plasminogen activation and metastasis 374
platinum compound 477
pO2 fluctuations 350
point mutations 687
polyethylene glycol 937
polyethyleneglycol 1545
polylysine conjugate 937
polymorphisms 702, 1096, 1502, 1517
polyomavirus 385
polypharmacotherapy 1013
polyunsaturated fatty acids 1686
pooled analysis 1638
poor PS patients 1827
population pharmacokinetics 787
positron emission tomography 262
potassium 1633
PPARγ 1409
preclinical models 2327
preconception exposure 1709
predictive assay 2277
predictive factors 977
predictive test 2264
predictors 1062, 1248
preterm birth 1664
prevention 2165
primary care 1650
primary chemotherapy 666, 977
primary language 641
procarbazine 248
prognosis 128, 140, 271, 298, 460, 470, 660, 681, 720, 1022, 1166, 1260, 1266, 1450, 1502, 2045
prognostic classification 1599
prognostic factors 546, 959, 2116
prognostic indices 1909
prognostic variables 284
progression-free and overall survival 465
prolactin 524
proliferation 128, 1035, 1493, 1817
proliferation index 2093
promoter 1086
prospective cohort study 847
prospective studies 1705
prostate cancer 106, 625, 968, 971, 1055, 1238, 1524, 1966
prostate tumours 687
proteasome expression 1116, 1783
protein catabolism 1116
protein kinase C 1152, 1418
proteolysis-inducing factor 1116
proteolysis-inducing factor (PIF) 1783
proteome 305
psychological impact 653
pyridinoline 1722
quality of life 50, 497, 641, 648, 971, 1843, 2202
quantitative real-time RT–PCR 271
quantitative RT– 1750
question prompt list 2069
radiation 593, 1215, 2305
radiation enhancement 1987
radiation protection 1979
radioimmunoassay 1927
radioiodine 258, 1638
radioligand 930
radiosensitisation 1352, 2305
radiosensitivity 2264, 2271
radiosensitization 577
radiosensitizer 746
radiotherapy 65, 298, 840, 2023, 2038, 2057, 2271
Raman spectroscopy 106
RARRES3 146
RAS 185, 1958
rat sarcoma 405
razoxane 262
RCAS1 546
RCC 1285
reactive oxygen species 1314
recombinant bacteria 1796
rectal cancer 870
recurrence 277, 1920
registries 1205, 1260
relapse 482
renal cell carcinoma 50, 1266, 1909, 2147, 2213
repeated events 781
residual disease 1185
resistance 206, 1147
response 277
retinoblastoma protein 120, 298
retinoblastoma tumour suppressor gene 135
retinoid 808
retinoyl glucuronide 412
reverse transcription–polymerase chain reaction 676
rhabdomyosarcoma 327
rhenium-188-HEDP 625
RhG-CSF 1008
RIG 1 146
rinse-fluid cytology of forceps and brush 1885
risk factors 519, 831, 2078
rituximab 1389
RNASEL gene 691
RNF11 1538
rosiglitazone 1409
RT112 593
RT–PCR 1457, 2104
rural health services 821
S-1 816, 2207
salted meat 1209
sarcoma 720
scFv 1130
Scotland 505
screening 23, 77, 1645
screening interval 88
seasonality 1200
second cancer 840
second-line treatment 2213
second primary malignancies 1638
senescence 1473
sentinel lymph node 1750
sentinel lymph node biopsy 648
sentinel node 676
seroprevalence 1248
serrated adenoma 152
serrated polyp 152
service delivery 653, 1650
sex steroids 385
sexual functioning 2202
side effects 1633
signal transducers and activators of transcription (STAT) 344
simvastatin 1855
skeletal-related events 2031
skin neoplasms 1205
SM-11355 1614
Small cell lung cancer 55, 2178
smoking 831, 1667, 2087
Smurf2 1538
socioeconomic status 1693
SOCS 524
SOCS-1 338
soft-tissue melanoma metastases 1620
soluble protein 1276
somatostatin receptor 258
South Asians 508
southern blot assay 676
SPARC molecular markers 1508
splice variant 1276
sponsorship 1405
squamous cell carcinoma 101, 834, 1048, 2078, 2244
squamous cell carcinoma of the vulva 2249
squamous dysplasia 1048
stage 1028, 1693
stage 4s 470
stage III 1457
stamps 2165
statistical methods 232
stem cells 1776
steroid receptors 268
stewed meat 1209
streptozocin 455
stroma 707
stroma-supported immunocytometric assay 763
superficial oesophageal cancer 2116
supportive care 1013
suppressor genes 687
surgery 460, 487
surveillance colonoscopy 1232
survival 55, 65, 487, 508, 533, 612, 660, 834, 864, 959, 1260, 1610, 1693, 1837, 1896, 2023, 2045, 2093
survival analysis 232, 271, 781
survivin 1743, 2244
susceptibility 1502
synergistic 746
synergy 944
systematic review 55, 959
T47D 593
tamoxifen 268, 277
tankyrase 713
targeting 1545
tazarotenic acid 808
T-cell precursor frequencies 1055
T-cell receptor (TCR) 1876
Tcf/Lef 1298
TCL1 1091
telomerase 713, 922
telomere 1091
temoporfin 398
temozolamide 248
temozolomide 922, 1901
temporal heterogeneity in pO2 350
testicular cancer 2202
testicular germ cell tumours (TGCTs) 2133
Tet system 2155
TGCT cytokine 915
TGFβ signalling 1538
therapeutic efficiency 625
therapy 1147, 1358, 2227
the systemic inflammatory response 612
thoracic radiation therapy 803
thyroid cancer 1638
thyroid carcinoma 2098
TIG3 146
TIMP 1817
tissue 1147
tissue samples 1722
TK 1776
TM4SF 158
TNF 1096
TNF-α 1123
toll-like receptor 2312
Tookad® 2320
topoisomerase II 1366
topoisomerase IIα 120
Topoisomerase IIα 666
topotecan 1002, 1789
toxicity 2057
TPA 1320
TRAIL 363, 2155
TRAIL receptors 363
trans-arterial chemoembolisation 1614
transforming growth factor-β 1345
transitional cell carcinoma 1305
trastuzumab 983
treatment 65, 470, 492
treatment choice 2219
treatment preference 2219
TRF1 713
TRF2 713
tropomyosin 860
truth disclosure 2069
tumorigenesis 1817
tumour antigens 1067, 1130
tumour biology 1508
tumour blood flow 1334
tumour doubling time 2184, 2254
tumour epitopes 1079
tumour growth rate 2254
tumour immunity 199, 1463
tumour marker 1927
tumour models 1581
tumour necrosis factor alpha 1987
tumour perfusion 262
tumour response 977
tumours 593, 930, 1276
tumour suppressor gene 146
tumour thickness 2019
tumour vessel 1334
TUNEL 1327
two-dimensional electrophoresis 305
tyrosinase 1457
tyrosine kinase 1783
tyrosine kinase inhibitor 246, 1889
tyrosine kinase phosphorylation 983
ubiquitination 1538
Uganda 502
ulcerative colitis 1232
ultrasound 1310
understanding 1450
understanding of disease status 641
‘unknown’ genes 1940
unresectable 1605
upper gastrointestinal cancer 497
urokinase plasminogen activator receptor 374
uterine endometrial cancer 546
uveal melanoma 1914, 1961
vaccination 199
validation 781
vascular endothelial growth factor 268
vascular endothelial growth factor (VEGF) 215
vascular invasion 1909
vascular permeability 1889
VDEPT 944
vegetables 1209
VEGF 1889
VEGF-B 891
vesicular monoamine transporter 1383
vinorelbine and paclitaxel 1566
virtual Northern 1940
visual acuity 2038
vitamin D 746, 968
vitamin E analogues 1822
vitamin K 1228
VMAT 1383
waiting times 492, 2184
weekly 1428
whitehall 1243
WHO classification 36
wide local excision 2019
WISP-1 314
Wnt-signalling 1298
Wnt signal transduction 152
women 2087
workload 15, 487
written information 1450
xenograft human tumour 1796
xenografts 577, 2289, 2327
xeroderma pigmentosum 333
young women 88
ZD 1839 246, 585
ZD6474 1889
zemplar 746
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 89. Br J Cancer 89, 2365–2370 (2003). https://doi.org/10.1038/sj.bjc.6601556
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6601556